




## ► PHARMA POOL

### Dr. James Bradner NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH APPOINTS PRESIDENT



Dr. James Bradner

Dr. James (Jay) Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, has been appointed president of the Novartis Institutes for BioMedical Research (NIBR) and a member of the executive committee of Novartis, effective March 1, 2016.

Dr. Bradner succeeds Mark Fishman, M.D., who will reach his contractual retirement age in March 2016 after a distinguished 13-year career at Novartis as the leader of the company's drug discovery and early clinical development efforts.

Dr. Bradner is on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute. He is a graduate of Harvard College and the University of Chicago Medical School. He did his residency in medicine at the Brigham & Women's Hospital, as well as fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute, where he has been on the faculty since 2005. Dr. Bradner has co-authored more than 130 scientific publications and 30 U.S. patent applications.

### Habib Dable BAYER APPOINTS HEAD OF U.S. PHARMACEUTICALS BUSINESS



Habib Dable

Bayer appoints Habib Dable as president of Bayer HealthCare Pharmaceuticals, the U.S.-based division of the global company's pharmaceutical business. Mr. Dable reports to Philip Blake, who has assumed the role of head of region Americas for Bayer HealthCare Pharmaceuticals and continues leading U.S. corporate functions as senior Bayer representative (SBR) in the United States, a position he has held since 2012.

Previously, Mr. Dable was global head of specialty medicine for Bayer HealthCare Pharmaceuticals, a role he held since 2013 and in which he was responsible for overseeing four therapeutic areas for the company — hematology, oncology, ophthalmology, and neurology. He began his career at Bayer in 1994 as a sales representative and moved on to hold a number of senior roles in Canada, Japan, and the United States, focusing on strategic planning, sales management, and global product marketing including successfully leading global product launches. Mr. Dable earned a master's of business administration degree from the University of New Brunswick in Canada.

## ► BIOTECH POOL

### Dr. Jeffrey Lawson HUMACYTE APPOINTS CHIEF MEDICAL OFFICER



Dr. Jeffrey Lawson

Humacyte, an innovator in biotechnology and vascular regenerative medicine, has appointed American Board of Surgery certified surgeon Jeffrey Lawson, M.D., Ph.D., as chief medical officer. Dr. Lawson, a clinical advisor to Humacyte over the past 10 years, oversees the medical and clinical development of the company's products.

Dr. Lawson recently served in various leadership roles at Duke University Medical Center. After receiving his doctorate in medicine from the University of Vermont College of Medicine in 1991 and his Ph.D. in cell and molecular biology from the same institution, Dr. Lawson completed his residency in general and thoracic surgery in 1999 at Duke University Medical Center. In 2002, he completed a fellowship in vascular surgery, also at Duke University Medical Center.

### Adam Rosenberg RODIN THERAPEUTICS APPOINTS CEO



Adam Rosenberg


Rodin Therapeutics, a biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, has appointed Adam Rosenberg as CEO. Mr. Rosenberg brings almost 20 years of entrepreneurial and transactional leadership, and will also be appointed to Rodin's board of directors.

Mr. Rosenberg most recently served as co-founder, director and CEO at Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology. Mr. Rosenberg holds a JD from the University of Virginia School of Law.


## ► AGENCY POOL

### Vanya Akraboff Kristine Ellis Kim Robinson Janet Vennari GIANT CREATIVE/STRATEGY MAKES PROMOTIONS

Giant Creative/Strategy, a full-service independent healthcare communications agency, has made several promotions. Vanya Akraboff has been promoted to senior VP, group creative director from VP, group creative director. Ms. Akraboff



Vanya Akraboff



Kim Robinson



Janet Vennari

has responsibility for the creative visionary for multiple accounts, and she has a proven track record of developing work that leads to market success for clients and brands. She has been with Giant since 2003.

Kristine Ellis has been promoted to senior VP, creative director from VP, group creative director. A key leader at Giant, Ms. Ellis works closely with clients and team members to achieve creative and strategic success, while contributing importantly to the culture and future direction of the agency. She has been with the agency since 2006.

Kim Robinson has been promoted to VP, management supervisor from management supervisor. She is an account leader responsible for delivering day-to-day results and strategic insight, as well as ongoing brand stewardship for United States and global business. She joined Giant in June 2012.

Janet Vennari has been promoted to senior VP, managing group director from VP, management supervisor. Ms. Vennari is the business unit lead overseeing multiple healthcare accounts with responsibility for strategically leading clients and account teams, and for generating both organic and new business. She has been with Giant since January 2014.

### Lee Davies MAKOVSKY NAMES DIRECTOR OF CLIENT SERVICES



Lee Davies

Makovsky, a leading independent integrated communications firm, has promoted Lee Davies, senior VP, to director of client services, health practice.

Mr. Davies is chair of the agency's flagship Quality Commitment Program, working with teams across practices to ensure quality client work and to identify the best resources to deploy for optimal results for Makovsky clients.

Before joining Makovsky, Mr. Davies was director, global media relations and product communications at Merck. <sup>PV</sup>



FOR BONUS CONTENT  
USE YOUR QR CODE READER  
OR GO TO  
[bit.ly/PV1115-Pool](http://bit.ly/PV1115-Pool)



# Your co-pay support program is half empty... if you can't show outcomes.

Our proprietary *Patient Feedback System* captures patient reported outcomes and delivers proven results – **45% NRx lift\***.

Maximize the impact of your co-pay support program.



\*MS Health Consulting; n=3,733

For more information, contact:  
Joe Abdalla, R.Ph. - Chief Commercial Officer  
joseph.abdalla@trialcard.com | 919-415-3103  
trialcard.com

**trialcard**<sup>®</sup>  
MARKET ACCESS SOLUTIONS  
Access | Acquisition | Adherence

(c) PharmaLinx LLC. Rights do not include promotional use.  
For distribution or printing rights, contact mwals@pharmavoices.com

## ► PHARMA POOL

### **Dr. Robert Fishman** **CORCEPT THERAPEUTICS CHIEF** **MEDICAL OFFICER**

Corcept Therapeutics, a pharmaceutical company engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, has appointed Robert Fishman, M.D., as its chief medical officer.

Dr. Fishman was most recently senior VP of clinical development at InterMune, where he led the pivotal clinical trial of Esbriet for the treatment of idiopathic pulmonary fibrosis.

Dr. Fishman brings to Corcept 19 years of product development experience. He trained in internal medicine at Deaconess Hospital, Boston, and completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital. He earned an M.D. from Stanford University School of Medicine.

## ► BIOPHARMA POOL

### **Dr. William Berg** **Jonathan Berndt** **Gregg Bernier** **EXELIXIS ANNOUNCES SENIOR** **LEADERSHIP HIRES**

Exelixis has made three high-level appointments as the company prepares for the potential commercialization of its lead compound, cabozantinib, for the treatment of advanced renal cell carcinoma. William Berg, M.D. has joined the company as senior VP of medical affairs, Jonathan Berndt as VP of sales, and Gregg Bernier as VP of marketing. Exelixis is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer.

As senior VP of medical affairs, Dr. Berg oversees medical affairs in the United States. He joins Exelixis after spending more than 12 years at Novartis, where he served in roles of increasing responsibility, including VP and franchise head within global medical affairs. Before entering the pharmaceutical industry, Dr. Berg served on the faculty of the Memorial Sloan Kettering Cancer Center (MSKCC), where he saw patients as part of the genitourinary oncology service, contributed to the MSKCC risk model for advanced RCC, and researched novel therapies for the disease. He earned his medical degree from Cornell University Medical College.

As VP of sales, Mr. Berndt leads all sales activities for cabozantinib and also directs U.S. co-promotion efforts for cobimetinib, including Exelixis' plans to field up to 25% of the cobimetinib U.S. salesforce in the event of a potential regulatory ap-

proval later this year. Mr. Berndt joins Exelixis with two decades of commercial sales experience in the biopharmaceutical industry, including multiple oncology product and line extension launches. Most recently, he served as senior director, oncology sales at Gilead Sciences, where he assembled and led the company's oncology sales team supporting Zydelig.

Exelixis' new VP of marketing Gregg Bernier leads the marketing group in its commercialization of cabozantinib for RCC. Mr. Bernier has more than 20 years of experience in biotech and pharmaceutical sales and marketing, primarily in oncology. Before joining Exelixis, he served as senior director of marketing at Medivation, where he led the launch of Xtandi for a new indication in metastatic castration-resistant prostate cancer.

### **Dr. Bharatt Chowrira** **SYNOLOGIC ACCELERATES BUSINESS GROWTH** **WITH APPOINTMENT OF PRESIDENT**

Synlogic, a privately-held biopharmaceutical company developing novel therapies based on synthetic biology and the microbiome, has appointed Bharatt Chowrira, Ph.D., as president of Synlogic.

In his role as president of Synlogic, Dr. Chowrira oversees the company's corporate and business development, alliance management, financial and legal operations, and he reports to Jose-Carlos (JC) Gutiérrez-Ramos, Ph.D., CEO. Dr. Chowrira brings more than 20 years of experience in research, corporate development, operations, financing, legal and licensing expertise. Dr. Chowrira was most recently the chief operating officer of Auspex Pharmaceuticals, which was acquired by Teva Pharmaceuticals in the spring of 2015.

Dr. Chowrira received a J.D. from the University of Denver's Sturm College of Law, a Ph.D. in molecular biology from the University of Vermont College of Medicine, and an M.S. in molecular biology from Illinois State University.

### **David Kaysen** **SUN BIOPHARMA NAMES** **PRESIDENT AND CEO**

Sun BioPharma, a biopharmaceutical company developing therapies for the treatment of pancreatic cancer, today announced that David Kaysen, a veteran healthcare executive, has been appointed president and CEO, as well as a member of the company's board of directors. Mr. Kaysen brings to Sun BioPharma more than 25 years of healthcare clinical development, commercial and public company achievements.

Before joining Sun, Mr. Kaysen was an advisor and senior executive for several domestic and European growth-oriented privately-held healthcare companies. He currently serves on the Board of Directors of four privately held companies.

### **Dr. Douglas Mayers** **Jeffrey Meckler** **COCRYSTAL PHARMA APPOINTS** **SENIOR EXECUTIVES**

Cocrystal Pharma, a biopharmaceutical company dedicated to creating novel small molecules for viral infections and liver diseases, has appointed Douglas Mayers, M.D., to the position of chief medical officer (CMO). This appointment reflects Cocrystal's continued growth as the company prepares to advance its HCV, influenza, and norovirus programs.

Dr. Mayers is a specialist in infectious diseases and has nearly 27 years of medical and clinical development experience spanning all phases of global clinical research and development and commercialization. Most recently, Dr. Mayers spent the past year at the U.S. Army Medical Research Institute of Infectious Diseases working with colleagues to discover and develop drugs against the Ebola virus. Prior to that he was the chief medical officer and executive VP at Idenix Pharmaceuticals.

Prior to joining the industry, Dr. Mayers held numerous academic and research positions. He also previously served on several NIH study sections and on FDA advisory committees. He is the author of more than 95 peer-reviewed publications/book chapters. Dr. Mayers received his M.D. from University of Pennsylvania.

In other company moves, Jeffrey Meckler has been appointed to the position of CEO. Mr. Meckler had been serving as Cocrystal Pharma's Interim CEO since March 31, 2015.

Mr. Meckler has more than 25 years of experience in life-sciences companies, including 17 years at Pfizer in a variety of positions, including manufacturing, systems, market research and corporate finance. He holds an M.S. in Industrial Administration from Carnegie Mellon University and a J.D. from the School of Law at Fordham University.

### **Dr. Stephen Villano** **PARATEK EXPANDS LEADERSHIP TEAM**

Paratek Pharmaceuticals has expanded its senior leadership team. The company announced that Stephen Villano, M.D. has joined as VP, clinical and medical affairs. Dr. Villano will be based out of the company's Philadelphia office. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry.

With more than 20 years experience in antiviral and anti-infective research, Dr. Villano previously served as VP, clinical research and development at ViroPharma, which became a subsidiary of Shire in 2014. Dr. Villano received his doctor of medicine degree at Johns Hopkins, where he also completed a residency in internal medicine and a fellowship in infectious diseases.

## ► BIOTECH POOL

### Gary Atkinson

#### LPATH APPOINTS INTERIM CEO

Lpath, which is developing lipid-targeted therapeutics, has appointed Gary Atkinson interim CEO of Lpath. Mr. Atkinson will continue to serve as Lpath's chief financial officer. Mr. Atkinson joined Lpath as chief financial officer in 2005, and he has more than 20 years of experience with life-sciences companies.

Before Lpath, he served as the chief financial officer for Quorex Pharmaceuticals, which was acquired by Pfizer. Mr. Atkinson began his career at Ernst and Young. He is a graduate of Brigham Young University.

### Dr. Cara Cassino

#### CONTRAFECT APPOINTS CHIEF MEDICAL OFFICER

ContraFect, a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, has appointed Cara Cassino, M.D., chief medical officer. Dr. Cassino brings extensive clinical development experience to ContraFect from global pharmaceutical leaders.

Dr. Cassino has extensive experience in the design and execution of drug development programs across a broad range of therapeutic areas, with the approval of more than 20 regulatory submissions in the United States and globally over the course of her career. Most recently, Dr. Cassino held the position of senior VP, global clinical development at Forest Laboratories.

Dr. Cassino received her medical degree from NYU. Dr. Cassino completed her internship and residency in internal medicine at NYU/Bellevue Hospital, followed by fellowship in pulmonary/critical care medicine at NYU and Mount Sinai Medical Center in New York City.

### Dr. Michael Cooreman Anita Treohan IMMUSANT NAMES TWO NEW R&D EXECUTIVES

ImmusanT, a company focused on restoring tolerance to gluten and overcoming the need for gluten-free diet in patients with celiac disease, announced the appointment of Michael Cooreman, M.D., Ph.D., as chief medical officer and Anita Treohan as director of clinical operations.

Dr. Cooreman brings to ImmusanT extensive experience in clinical development and translational medicine. As chief medical officer, he leads all clinical development programs, including the development of Nexvax2, ImmusanT's lead product candidate for the treatment of celiac disease. Ms. Treohan joins the company with diverse global clinical development and strategic experience

across multiple therapeutic areas. As director of clinical operations, Ms. Treohan is responsible for the management of ImmusanT's clinical programs, including the upcoming Phase II trials of Nexvax2.

Dr. Cooreman joins ImmusanT from Mitsubishi Tanabe, where he served as executive director for clinical research and head of metabolism, infectious diseases and oncology. Dr. Cooreman earned his doctor of medicine at the University of Leuven Medical School in Belgium and his doctorate in microbiology at Heinrich Heine University in Duesseldorf, Germany.

Most recently, Ms. Treohan served as director of clinical operations at Forum Pharmaceuticals, where she was the operational lead for several clinical development assets for neurodegenerative and psychiatric diseases. Ms. Treohan holds a master of public health in epidemiology/biostatistics and social behavioral sciences from Boston University.

### Chaim Lebovits

#### BRAINSTORM APPOINTS CEO

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, has appointed Chaim Lebovits, who has been serving as the company's president since July 2007, as CEO. Mr. Lebovits succeeds Dr. Tony Fiorino, who is anticipated to remain with the company in an executive scientific role.

Mr. Lebovits previously served as principal executive officer of BrainStorm from August 2013 to June 2014. Through ACCBT Corp. and ACC Holdings

International, Mr. Lebovits has invested to date more than \$5 million in BrainStorm. Mr. Lebovits is chairman and CEO of ACC Holdings International, an investment company with several holdings in biotech and natural resource.

## ► CRO POOL

### Dr. Randy Anderson

#### CHILTERN ANNOUNCES EXPANSION IN ENDOCRINOLOGY AND METABOLISM

Chiltern, a global contract research organization, is expanding its clinical development services in endocrinology and metabolism and has named Randy Anderson, Ph.D., as senior VP of scientific affairs.

With nearly 30 years of industry experience, Dr. Anderson is an expert in diabetes and other endocrine/metabolism disorders. A board director for JDRF International, he also serves on multiple scientific advisory boards for pharmaceutical companies with endocrine products. He joins Chiltern after 18 years with another major clinical research organization, where he provided scientific leadership for the endocrinology and metabolism therapeutic area and was a key contributor on hundreds of trials and products. In addition to being the therapeutic area leader for endocrinology and metabolism, Dr. Anderson serves as Chiltern's administrative leader for its other scientific affairs experts across all therapeutic areas. <sup>PV</sup>

## Searching for the right audience for your next e-mail campaign?

### Target PharmaVOICE Readers with your E-mail Marketing Campaign

- Segment our opt-in e-mail database of 65,000+
- 20% off multiple emails
- 50% off all resends
- Best practices for better ROI
- Design and html coding available

Call 215-321-8656 or e-mail  
[mwalsh@pharmavoices.com](mailto:mwalsh@pharmavoices.com)  
discuss your next email promotion with Marah Walsh.

PharmaVOICE



WE  
ARE  
NOT  
HIRING  
WE ARE HANDPICKING

(c) PharmaLinx LLC. Rights do not include promotional use.  
For distribution or printing rights, contact mwals@pharmavoices.com

WE ARE AN AD AGENCY THAT IGNITES BRANDS IN BOLD AND BEAUTIFULLY DISRUPTIVE WAYS. AND WE'D NEVER LET JUST ANYBODY DO THAT. [inVentivHealth.com/PALIO](https://www.inVentivHealth.com/PALIO).

**PALIO**  
ignited  
INVENTIV HEALTH